Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Daniel C. Montano Announces His Victory over CVBT/VT
Despite years of fraudulent and frivolous lawsuits it appears that Daniel C. Montano is now victorious over the crooks that run Cardiovascular Biotherapeutics/Venturis Therapeutics.
Daniel C. Montano has been awarded an over $1 million dollar judgment against CVBT/VT as a result of the frivolous lawsuit that they had originally filed.
Daniel C. Montano's more than $1,000,000 dollar judgement against Cardiovascular BioTherapeutics/Venturis Therapeutics has been confirmed by the United States Federal Court System.
Dan Montano's clear victory over CVBT/VT could result in a forced debtors exam against CVBT/VT in order for Montano to collect on his judgement.
Daniel C. Montano has announced that he has won a $1 million dollar judgement against CVBT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
Daniel C. Montano announces that he wins a ONE MILLION DOLLAR JUDGEMENT against Venturis Therapeutics(fka CVBT)
In an unfortunate turn of events for our administration, the arbitration case initiated by Venturis Therapeutics against Mr. Daniel Montano has resulted in Dan Montano winning a one million dollar judgement against Venturis Therapeutics as well as attorneys' fees and costs; confirmed by the US Federal Court.
Mr. Montano is now pursuing the involuntary collections of his judgment against Venturis, which will include a judgment debtor discovery against Venturis Therapeutics so that Mr. Montano can seize the assets of the company and satisfy the terms of his judgement.
Even worse for Venturis: Other litigation initiated by Venturis against Mrs. Montano and Zhittya Genesis Medicine (commonly referred to as Zhittya) has been DISMISSED by the Nevada State courts.
THIS IS A CLEAR VICTORY FOR DAN MONTANO AND ZHITTYA. After this judgement I will be surprised if Venturis Therapeutics makes it through 2021
Daniel C. Montano announced that he has won a judgement against CVBT/VT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
CVBT/VT has lost EVERY lawsuit to Zhittya Genesis Medicine/Zhittya Regenerative Medicine and Daniel C. Montano
Since Dan Montano left the company in 2014 to start Zhittya, our management has consistently attempted to harm the new company. After seven years of lawsuits, all of them have been ruled in favor of Zhittya Genesis as well as their CEO, Dan Montano. The most recent ruling has resulted in a $1 million dollar judgement against CVBT/VT, confirmed by the US Federal Court. This confirmation gives Zhittya and Dan Montano the ability to do a debtors exam in May.
CVBT/Venturis Therapeutics Misconduct results in Dan Montano's $1 million dollar judgement against CVBT/VT
Daniel Montano, founder of CVBT in 1998, left the company in 2014 to found Zhittya Genesis Medicine. CVBT/VT has since filed countless lawsuits, only to lose EVERY SINGLE LAWSUIT to Daniel C. Montano and Zhittya Genesis Medicine. The most recent lawsuit CVBT/Venturis Therapeutics filed against Zhittya Genesis Medicine and Daniel C. Montano has resulted in Zhittya Genesis Medicine being dismissed from the lawsuit, and Daniel Montano having a $1 million dollar judgement against CVBT/VT for their misconduct.
Zhittya Genesis Medicine DISMISSED from CVBT Lawsuit
In a lawsuit Cardiovascular Biotherapeutics filed against Zhittya Genesis Medicine, the Nevada State Court has dismissed Zhittya Genesis Medicine from the lawsuit. The lawsuit had that claimed that Zhittya Genesis Medicine was stealing trade secrets from CVBT which has since been thrown out of court.
The case was easily dismissed after CVBT'S OWN EXPERTS TESTIFIED THAT ZHITTYA GENESIS MEDICINE STOLE NOTHING FROM CVBT.
In a clear victory for Zhittya Genesis Medicine and Dan Montano, whose $1 million dollar judgement against Venturis Therapeutics will likely result in the downfall of CVBT, investors, including myself are wondering if CVBT will make it through 2021.
THE UNITED STATES FEDERAL COURT HAS CONFIRMED DAN MONTANO'S ONE MILLION DOLLAR CLAIM AGAINST CVBT/VENTURIS THERAPEUTICS
Furthermore, with Zhittya Genesis Medicine and Mrs. Montano being ENTIRELY DISMISSED from the lawsuits that Venturis brought fourth there is a clear path for Mr. Daniel Montano to forcibly collect on his 1 million dollar claim. Venturis is at the hands of Dan Montano! Why were we not made aware of this? Why is our administration so quick to announce when lawsuits are filed but not when we are miserably defeated and punished for our defeat?
I worry that Mr. Montano will wipe Venturis off the face of the map with his new ability to forcibly collect on his one million dollar award which has been confirmed by the United States Federal Court.
Debtors Exam for CVBT
Zhittya Genesis Medicine Inc., (formerly known as Zhittya Regenerative Medicine), competitor to Cardiovascular Biotherapeutics Inc., has announced its CEO, Daniel C. Montano, has been awarded an over $1 million legal judgement, confirmed by the US Federal Court, against CVBT and its new name, Venturis Therapeutics.
Mr. Dan Montano is now pursuing the involuntary collections of his judgements against CVBT.
Zhittya Genesis Medicine also announced that ALL legal allegations made against Zhittya Genesis Medicine have been DISMISSED by the judge.
After seven years of lawsuits by CVBT against Zhittya it is clear that CVBT has come out as the ultimate loser after this judgement against them for $1 million. In all this time, CVBT has FAILED TO CONDUCT CLINICAL TRIALS, MANUFACTURE THE DRUG, OR PAID ANY PART OF ITS $30 MILLION IN DELINQUENT BILLS.
Daniel C. Montano wins a ONE MILLION DOLLAR JUDGEMENT against Venturis Therapeutics(fka CVBT)
In an unfortunate turn of events for our administration, the arbitration case initiated by Venturis Therapeutics against Mr. Daniel Montano has resulted in Dan Montano winning a one million dollar judgement against Venturis Therapeutics as well as attorneys' fees and costs; confirmed by the US Federal Court.
Mr. Montano is now pursuing the involuntary collections of his judgment against Venturis, which will include a judgment debtor discovery against Venturis Therapeutics so that Mr. Montano can seize the assets of the company and satisfy the terms of his judgement.
Even worse for Venturis: Other litigation initiated by Venturis against Mrs. Montano and Zhittya Genesis Medicine (commonly referred to as Zhittya) has been DISMISSED by the Nevada State courts.
THIS IS A CLEAR VICTORY FOR DAN MONTANO AND ZHITTYA. After this judgement I will be surprised if Venturis Therapeutics makes it through 2021.
And that is the bottom line. Funny how no one could dispute my earlier post: Here is a link that is hard to dispute: https://uploads-ssl.webflow.com/5d929ea754fd0f4955087956/608c36b4f0b7c7ffa9bb6319_CAD%20patent%20PR%20final%204.29.2021.pdf
Evidently many are buying into Montano's clones promoting his new company. Hopefully they buy his IPO to satisfy his debt to Venturis.
CEO, Calvin Wallen, has assigned his $2.5 million court judgement to VT which means that VT is now going after Dan Montano for the balance they are owed of $1.7 million. Parents should pay particular attention to the fact that their children could be in pearl due to Conman's proclivity of driving through parking lots full of soccer moms and their kids at 50+ MPH.
Refer to the Worst CEO Ever YT video.
$1,100,000 awarded to Daniel C. Montano by the US Federal Court against CVBT/VT
The United States Federal court has confirmed Daniel C. Montano's $1.1 million dollar judgement against CVBT/VT as a result of their fraudulent and frivolous lawsuit claiming that Daniel C. Montano's IP was not his.
The US Federal Court not only confirmed that Daniel C. Montano has a $1 million dollar (non-off-settable) judgement against CVBT/VT, but that Daniel C. Montano and Zhittya Genesis Medicine own all of their IP.
Daniel C. Montano announces that the US Federal Court has confirmed his IP
The United States Federal Court has confirmed the ruling in favor of Daniel C. Montano citing that Dan Montano owns all of the IP that he and his company, Zhittya Genesis Medicine are developing.
The United States Federal Court's confirmation comes as a result of Cardiovascular Biotherapeutics/ Venturis Therapeutics' own management team testifying in favor of Daniel C. Montano, stating that the IP that Dan Montano and Zhittya Genesis Medicine have been developing are 100% theirs.
Daniel C. Montano Announces His Victory over CVBT/VT
Despite years of fraudulent and frivolous lawsuits it appears that Daniel C. Montano is now victorious over the crooks that run Cardiovascular Biotherapeutics/Venturis Therapeutics.
Daniel C. Montano has been awarded an over $1 million dollar judgment against CVBT/VT as a result of the frivolous lawsuit that they had originally filed.
Daniel C. Montano's more than $1,000,000 dollar judgement against Cardiovascular BioTherapeutics/Venturis Therapeutics has been confirmed by the United States Federal Court System.
Dan Montano's clear victory over CVBT/VT could result in a forced debtors exam against CVBT/VT in order for Montano to collect on his judgement.
How do we invest in Zhittya? Seems to be no replies to any messages to there website. Are they are zombie company as well?
The Big Lie Part 2, the Venturis/CVBT version:
The Venturis Therapeutics/CVBT version of The Big Lie is that there are allegedly two pivotal clinical trials ongoing in coronary artery disease and diabetic foot ulcers.
That's a "PANTS ON FIRE" lie.
Yet this lie is being anonymously promoted publicly by CVBT supporters (who in my opinion are the leadership of this company who are more than happy to lie when their names are kept anonymous, rather than lie to our face using their real name such as "Grant Gordon").
For the record, Venturis/CVBT has not run a single clinical trial since 2007. Not one patient has been treated in nearly 15 years! One cannot be running an ongoing pivotal trial in 2021 if one hasn't run a single clinical trial since 2007.
I issued a public challenge to the liar and coward who anonymously made that absurdly false statement. And so far, the liar/coward has refused to respond.
Here is my question to the liar/coward: Would you please indicate the month and year of the most recent patients treated in these so-called "pivotal trials"? And tell us what hospital(s) they were treated in?
Of course, we will never get a response to this question. Because the honest, correct answer is that there are ZERO ongoing clinical trials, there have been no clinical trials run since 2007, that Venturis Therapeutics is a zombie company that exists only in cyberspace, that Venturis is insolvent, illiquid, and all but dead, that Calvin Wallen and Grant Gordon are con men and liars, and that the so-called "valuable patents" are a pile of steaming sheisse that no one wants or cares about because they're laughably worthless. If these patents are so valuable as is anonymously claimed (and note that claim is never made when someone's name is attached to it), tell us, why has Venturis had them for several years now yet never been able to monetize them in terms of investment, partnering deals, and/or sale of the patents? Easy - because they're a joke and anyone who's actually a biotech person knows that in a nanosecond. The patents tell us what happens in the real world when a failed oil and gas buffoon decides to play biotech.
If Venturis leadership is willing to publicly lie (albeit anonymously) about something so clearly absurd and verifiably untrue as ongoing clinical trials, there's literally nothing they won't lie about. And that's why no investors or partners will ever touch this company--because there's literally nothing that can be trusted, let alone that everything here is worthless.
Soon this zombie company will be put out of all of our misery.
For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157492465
Zhittya Genesis Medicine announces it will begin its Phase I trial in Parkinson's disease in the coming months. When will Venturis start their trial?
Zhittya Genesis Medicine announces it plans to seize Venturis assets in the near future to settle the judgment Daniel C Montano won.
Here is a link that is hard to dispute: https://uploads-ssl.webflow.com/5d929ea754fd0f4955087956/608c36b4f0b7c7ffa9bb6319_CAD%20patent%20PR%20final%204.29.2021.pdf
Appears Venturis is ahead on this treatment.
Daniel C Montano announces that he will definitely pursue Venturis and seek to seize assets from the company.
Daniel C Montano announces that Zhittya Genesis Medicine will give new webinars to the company’s supporters in Latin America this month.
Daniel C. Montano announces Zhittya Genesis Medicine will submit for a trial in diabetic foot ulcer patients in Mexico.
Daniel C Montano announces that clinical trials are approved and set to start in Monterrey, Mexico.
Yes, announcements and reality are two different things, indeed. The company's supporters are FRAUDULENTLY claiming there are two ongoing pivotal trials in heart disease and diabetic foot ulcers, when in fact there are NO ONGOING CLINICAL TRIALS. In fact, Venturis/CVBT has not treated a single new patient in nearly 15 years.
It's interesting that no one who is a supporter of this company has risen to the challenge indicated in my earlier posting asking someone to name the month, date, and hospital locations of the most recent patients treated in these allegedly "ongoing pivotal trials." There's a reason why: BECAUSE THE CLAIM OF VENTURIS ONGOING CLINICAL ACTIVITY IS A FLAT-OUT LIE.
For more information:
The Venturis Therapeutics / CVBT version of THE BIG LIE:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163577011
Here's more information about the horrific current state of affairs:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157492465
Announcements and reality are 2 different things. Zhittya blitz is a build up to an IPO that will finance Montano's shenanigans.
Bottom line is Montano owes CVBT 1.7 million after the reduction in the lawsuit. This is reality.
Daniel C. Montano announced that he has won a judgement against CVBT/VT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
Zhittya Genesis Medicine announces that company representatives will be manning a booth and meeting investors face-to-face at The MoneyShow being held in Orlando, FL from June 10 to 12, 2021.
Zhittya Genesis Medicine announces it will be presenting in May 2021 at two separate MoneyShow virtual meetings. See how they stack up against Venturis!
Zhittya Genesis Medicine announces it has initiated its new studies examining delivering FGF to the brain through the nasal route.
Zhittya Genesis Medicine announces that Dan Montano will be presenting at the Family Offices Investment Summit, in Monaco, being held June 30 to July 2, 2021.
I agree Venturis is light years ahead and a buy out or breakthrough is in the near future. As for Montano's latest company seems like smoke and mirrors.
There is a greater chance that a heart disease patient will be dosed sometime next week in Venturis Therapeutics's non-existent pivotal trial that delusional Venturis management apologists are claiming is underway (or is it the company's leadership itself?), than "some Big Pharma makes a play for Venturis."
Big pharma would never touch a company that has a corrupt CEO and leadership team who is alleged to have stolen $14 million, where the words fraud, lies, lawsuits, kickbacks, etc., are all routine parts of the discussion.
But we're allowed our alcoholic delusions. Isn't that right, Grant?
For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157492465
I think Dan has imploded with the latest Patent grant.
He knows it's only a matter of time - some Big Pharma makes a play for Venturis.
Zhittya Genesis Medicine announces it has won all lawsuits against CardioVascular BioTherapeutics (CVBT-VT) and the court has ruled that Zhittya owns 100% of its own IP relating to FGF-1. Zhittya is proceeding on using FGF-1 for Therapeutic Angiogenesis for 10 separate medical indications.
Interesting comment, johnnymcgriffen347. I don't know if you've noticed, but such behavior is consistent with Schizophrenic Alcoholic Dementia. If you're right johnnymcgrifffen347, it would suggest that Grant Gordon is suffering from Schizophrenic Alcoholic Dementia (SAD) as well as Alcoholic Impotence (AI).
While I've heard consistent rumors from Venturis sources that Grant was pushing Calvin Wallen to pursue the Alcoholic Impotence indication for Venturis Therapeutics's drug which insiders believe was as much for personal reasons, this suggests that Grant's situation is even more dire than outsiders may have realized. I did some reading, and according to the medical literature, patients who are suffering from Schizophrenic Alcoholic Dementia have usually also reached End-Stage Liver Disease (ESLD). It's apparently pretty rare for someone to have SAD who has not already reached the point of ESLD. And we know what happens to ESLD patients.
Sad!
The claims were probably made by our drunkard Grant Gordon. He is a known fraudster and convicted liar, but judging by how horribly inaccurate his statements are about the clinical trials he might just be in a depressed drunken stupor because he can’t produce children.
THE BIG LIE, Venturis/CVBT version:
I see that we now have the Venturis/CVBT version of The Big Lie. Supporters of Venturis Therapeutics are claiming that the company is currently in two ongoing pivotal clinical trials in two different indications.
THAT IS AN OUTRIGHT LIE.
Venturis/CVBT has not run a single clinical trial since 2007. You can not be running an ongoing pivotal trial in 2021 if you haven't run a single clinical trial since 2007.
Here is my question to those who are making this false claim that there are two ongoing pivotal trials taking place: Would you please indicate the month and year of the most recent patients treated in these so-called "pivotal trials"? And tell us what hospital(s) they were treated in?
Let's see what answers are provided here.
For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157492465
Zhittya Genesis Medicine announces it has won all lawsuits against CardioVascular BioTherapeutics (CVBT-VT) and the court has ruled that Zhittya owns 100% of its own IP relating to FGF-1. Zhittya is proceeding on using FGF-1 for Therapeutic Angiogenesis for 10 separate medical indications.
Zhittya Genesis Medicine announces it has won all lawsuits against CardioVascular BioTherapeutics (CVBT-VT) and the court has ruled that Zhittya owns 100% of its own IP relating to FGF-1. Zhittya is proceeding on using FGF-1 for Therapeutic Angiogenesis for 10 separate medical indications.
Zhittya Genesis Medicine announces it has won all lawsuits against CardioVascular BioTherapeutics (CVBT-VT) and the court has ruled that Zhittya owns 100% of its own IP relating to FGF-1. Zhittya is proceeding on using FGF-1 for Therapeutic Angiogenesis for 10 separate medical indications.
Zhittya Genesis Medicine announces it has won all lawsuits against CardioVascular BioTherapeutics (CVBT-VT) and the court has ruled that Zhittya owns 100% of its own IP relating to FGF-1. Zhittya is proceeding on using FGF-1 for Therapeutic Angiogenesis for 10 separate medical indications.
The introduction says Mr. Gordon is unable to have children and is an alcoholic is that true???
Wow the introduction is pretty convincing on not investing, I’m definitely not putting any more money into this fraud of a company!
Status of CVBT/VT Clinical Trials?
As an outsider it’s hard to triangulate on the true status of CVBT/VT clinical trials.
Let us turn to the tangible with CVBT/VT clinical programs. Absent any official Company news releases from CVBT/VT on the resuming of a clinical trial for coronary heart disease and/or wound healing in diabetic foot or venous stasis ulcers we have nothing but innuendo from this site. Investors Hub recent posts refer to these trials as pivotal (which are either P-2B or P-3) and according to the guidelines of clinicaltrials.gov data base, sponsors are required to update the clinical trials.gov data bases for trials at this stage of development. Some P-1 trials are still likely exempt from posting. It appears that the last clinicaltrials.gov update for all three CVBT/VT clinical programs; peripheral arterial disease (PAD), coronary artery disease (CAD) and wound healing of diabetic and venous stasis ulcers was in November of 2019.
CVBT CAD Trial:
https://clinicaltrials.gov/ct2/show/NCT00117936?term=cvbt&draw=2&rank=4
CVBT Treatment of diabetic or venous stasis ulcers:
https://clinicaltrials.gov/ct2/show/NCT00425178?term=cvbt&draw=2&rank=3
CVBT PAD Trial:
https://clinicaltrials.gov/ct2/show/NCT00424866?term=cvbt&draw=2&rank=2
The wound healing trial is reported to be complete. According to clinicaltrials.gov it was an 8-patient trial and by drug development standards would not be considered pivotal in nature. A new P2/3 wound healing protocol has not been posted to the site. If there is a P-2/3 wound healing trial ongoing in the US and not posted it would be in violation of the clinicaltrials.gov guidelines. Same is true for a P-2 trial in CAD. The US FDA in a recently issued guidance April 28, 2021 (see link below) states they intend taking action against sponsors who do not populate the clinical trials.gov site with the required information in a timely fashion.
https://www.fda.gov/news-events/press-announcements/fda-takes-action-failure-submit-required-clinical-trial-results-information-clinicaltrials.gov
If any new clinical trial(s) is/are under way under CVBT’s sponsorship, then good for CVBT/VT and its shareholders.
If not, when might they begin and what are the gating events associated with the restart?
Also, JohnnyM if you look at the old video that was compiled by shareholders in Singapore you'll see that the reason that Daniel C. Montano is affectionately known as Conman Dan is that he has actually been CONVICTED OF FRAUD. See the section at 4.32 titled "Dan Montano Loots Baraban Securities, Still Owes More Than $1.1m".
I hope you find this useful JM.
DAN MONTANO'S FRAUD CONVICTION
It’s somehow worse. Somehow a significant portion of the introduction is illegible as a result of the incompetence of a drunkard man, whose kids cannot show him how to format text correctly because he is impotent. Someone needs to fix the portion of the intro that was made by JBDC
Odd, I can’t even read the first part of the intro. The formatting is horrible, it looks like it was made by a middle-aged alcoholic. Someone should fix the formatting on it or get their kids to fix it (if they are able to have any).
Now for the truth - REDUX
Conman Dan raised no cash for CVBT (as was). The seed capital & all other raises were done by Grant Gordon, the co-founder & present director of CVBT/VT. Grant Gordon also raised all the cash since 2014 when the shareholders kicked out Conman Dan. 95% of the votes were to the new management team who saved the company on behalf of the shareholders.
VT has lost zero lawsuits to Conman. The conman was awarded $800,000 in back wages via an arbitration case, not a lawsuit, which reduces the award Calvin Wallen won (he was awarded $2.5m against Conman) to a net $1.7m. Mr. Wallen very kindly assigned the award to VT. VT is now going after Conman for payment of the $1.7m.
Shittya was kicked in the teeth by the US FDA when they tried to seek permission to conduct trials in USA. Shittya were forced to go to Mexico to conduct a non-FDA Phase 1 trial. To date Conman's Shittya has treated ZERO patients. VT on the other hand has treated over 300 patients successfully with ZERO side effects. VT is also moving into a Phase 2b/3 trial under the auspices of the FDA. As per previous posts, VT is 5 laps ahead of Shittya in a 6 lap race.
p.s. & yes, Conman is still a bankrupt (BK) 8 years after declaring BK.
Followers
|
39
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3648
|
Created
|
04/08/05
|
Type
|
Free
|
Moderators |
VENTURIS THERAPEUTICS (formerly Cardiovascular
Biotherapeutics or CVBT) is a dead, zombie company
that hasn't run a single clinical trial in nearly 15
years. Not even one patient (!) has been treated
since 2007. Venturis Therapeutics is insolvent,
illiquid, and is controlled and run by an individual
who was accused by the U.S government of
embezzling $14 million from his previous company.
Venturis' lawyer, Barry Cannaday of Dentons (one
of the largest law firms in the U.S.), withdrew from
representing Venturis in April 2021 because Dentons
is owed over $200,000 by Venturis, and Mr. Cannaday
attested that "there are currently no assets or
revenue streams" to pay Dentons. Yet anonymous
advocates for Venturis (who I personally believe are
the company's desperate leadership) lie about public
facts that are easily verifiable. One of the most
absurd false claims is that there are (allegedly) two
ongoing pivotal clinical trials (see that particular
false claim below). These "clinical trials" exist only
in cyberspace but not in the real world the rest of us
(including Dentons) live in. That said, enjoy the
entertainment that lies below. Hopefully it gives you
some good laughs - that's about all that's left from
this dead, zombie company. Enjoy!
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS OVERVIEW
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage biopharmaceutical company advancing novel
therapeutics to address diseases such as diabetic wounds, severe ischemic heart disease and
peripheral artery disease. Our pre-clinical therapeutic programs include erectile dysfunction,
infarct stroke, degenerative disk disease and Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on targeted delivery of next generation
molecules which will improve the quality of life for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when administered to ischemic organs and
tissues. These anatomical targets are shown in our pipeline section.
vt.care
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |